

Sanofi at  
**EASD**  
**54<sup>TH</sup>**  
 ANNUAL MEETING  
**BERLIN** OCTOBER 1-5

**BRIGHT** FIRST HEAD-TO-HEAD RANDOMIZED CONTROLLED TRIAL, COMPARING **TOUJEO® (INSULIN GLARGINE 300 UNITS/ML) VS. INSULIN DEGLUDEC 100 UNITS/ML, SHOWS SIMILARITIES AND DIFFERENCES**



**929** adults  
 diabetes  
**type 2**  
 insulin-naïve

First weeks of **insulin titration** are critical

May contribute to Better treatment **adherence** and improved long-term **outcomes**



**Glycemic control** Weeks 0-24

Difference between treatments -0.05% [95% CI -0.15 to 0.05%]  
 p<0.0001 for non-inferiority [0.3% margin for non-inferiority]

**Anytime hypoglycemia** Weeks 0-24

**Event rates**  
 Odds Ratio: 0.69 (95% CI, 0.45 to 1.08, not significant)  
**Incidence**  
 Odds Ratio: 0.76 (95% CI, 0.53 to 1.08, not significant)

**Lower anytime hypoglycemia** rates for **Gla-300** during **titration** period  
 Weeks 0-12 Odds Ratio: 0.57 (95% CI, 0.34 to 0.97, significant)  
**43%**

Follow us @SanofiDCV



Reference: Rosenstock J, et al. Diabetes Care. 2018, DOI: 10.2337/dc18-0559.

